The best indicator for ResMed (RMD)
We backtested 366 indicators across daily, weekly and hourly charts on real ResMed (RMD) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Detrended Price Osc.
On the weekly chart, this is the strongest risk-adjusted edge we found for ResMed (RMD) over ~31.1 years — trailing buy-and-hold by 4.7% CAGR.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for ResMed (RMD) — trailing buy-and-hold by 10.1% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Detrended Price Osc. ✓ | Weekly | 16.0% | 0.72 | -40.3% | 56.1% | 180 | -4.7% |
| 2 | DeMarker ✓ | Daily | 14.3% | 0.69 | -34.6% | 71.8% | 110 | -6.5% |
| 3 | Markov Regime ✓ | Daily | 18.6% | 0.64 | -61.6% | 63.9% | 119 | -2.3% |
| 4 | MA Envelope ✓ | Daily | 13.3% | 0.62 | -63.6% | 67.7% | 217 | -7.5% |
| 5 | QQE ✓ | Weekly | 17.0% | 0.62 | -62.1% | 57.8% | 90 | -3.7% |
| 6 | SMA 20/50 Cross ✓ | Weekly | 17.1% | 0.66 | -54.5% | 78.6% | 14 | -3.6% |
| 7 | QQE ✓ | Daily | 17.3% | 0.61 | -59.3% | 45.8% | 454 | -3.5% |
| 8 | ROC (60) ✓ | Weekly | 15.8% | 0.61 | -54.5% | 67.7% | 31 | -4.9% |
| 9 | CCI (100) ✓ | Weekly | 15.6% | 0.61 | -55.2% | 47.6% | 21 | -5.2% |
| 10 | Lorentzian Classification ✓ | Weekly | 15.1% | 0.61 | -59.5% | 55.6% | 250 | -5.6% |
| 11 | Volume Flow Indicator ✓ | Daily | 15.4% | 0.6 | -57.3% | 47.8% | 67 | -5.4% |
| 12 | Murrey Math Lines ✓ | Daily | 12.2% | 0.6 | -52.8% | 83.1% | 77 | -8.6% |
| 13 | Williams %R ✓ | Daily | 12.0% | 0.59 | -66.3% | 66.0% | 194 | -8.9% |
| 14 | Williams %R ✓ | Weekly | 11.1% | 0.59 | -40.3% | 76.9% | 39 | -9.7% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For ResMed (RMD), Detrended Price Osc. on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.